BIM polymorphism is strongly linked to a poor clinical reaction for EGFR TKIs in EGFR-mutant NSCLC patients; hence, BH3-mimetic ABT-737 returns BIM functionality EGFR-TKI sensitivity (232). This evidence concerns the gene EGFR and non-small cell lung carcinoma.